Therefore, in this study, we aimed to analyze the treatment efficacies and toxicities of combination therapy in patients with advanced EGFR-mutant lung adenocarcinoma (LUAD) with MET overexpression after progression from EGFR TKI treatment in the real-world setting. Here, MET is linked to lung adenocarcinoma.